Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model.

Rodrigo, M J; Cardiel, M J; Fraile, J M; Mendez-Martinez, S; Martinez-Rincon, T; Subias, M; Polo, V; Ruberte, J; Ramirez, T; Vispe, E; Luna, C; Mayoral, J A; Garcia-Martin, E

Rodrigo, M J; Cardiel, M J; Fraile, J M; Mendez-Martinez, S; Martinez-Rincon, T; Subias, M; Polo, V; Ruberte, J; Ramirez, T; Vispe, E; Luna, C; Mayoral, J A; Garcia-Martin, E.

Afiliación

Rodrigo MJ; Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain. mariajesusrodrigo@hotmail.es.

Biomater Sci ; 8(22): 6246-6260, 2020 Nov 21.

Article en En | MEDLINE | ID: mdl-33016285

Asunto(s)

Glaucoma; Fármacos Neuroprotectores; Animales; Tartrato de Brimonidina; Estudios de Seguimiento; Glaucoma/tratamiento farmacológico; Ratas; Silicatos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Glaucoma / Fármacos Neuroprotectores Tipo de estudio: Observational_studies / Prognostic_studies Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google